This post was originally published on this site
Organic net sales grew 11.9%, including 11.4% from increased unit volume and 0.5% from higher prices.
MedSurg and Neurotechnology net sales came in at $2.9B, representing a 12.2% year-over-year increase. Orthopaedics and Spine net sales grew 9.9% year-over-year to $2.1B.
“We delivered strong organic sales growth in the second quarter as demand for our products remains strong. We are back on our margin expansion pathway, and our supercycle of innovation is going well,” said CEO Kevin A. Lobo.
The company expects full 2023-year EPS in the range of $10.25-$10.45, compared to the consensus estimate of $10.16. Full-year organic net sales growth is seen at 9.5%-10.5%.
By Davit Kirakosyan
